Literature Review: Application of Particular Solvents in Injection Formulations: DMSO, PEG, and Pyrogen Free Water
DOI:
https://doi.org/10.70062/globalhealth.v2i2.210Keywords:
Injectable Solvent, DMSO, PEG, Pyrogen-Free Water, Sterile FormulationAbstract
The selection of appropriate solvents in sterile injection formulations plays a pivotal role in determining the stability, efficacy, and safety of pharmaceutical products. Among the commonly utilized solvents, Dimethyl Sulfoxide (DMSO), Polyethylene Glycol (PEG), and pyrogen-free water exhibit distinct physicochemical properties and functional roles. This study aims to analyze the characteristics, functions, and implications of these three solvents within the context of sterile injectable preparations. The research methodology involves a comprehensive review of six peer-reviewed scientific articles published within the last five years, focusing on solvent performance, compatibility, and safety profiles. Findings reveal that DMSO is highly effective in dissolving lipophilic compounds due to its strong solvating capacity. However, its use at elevated concentrations may lead to irritation and cytotoxicity, necessitating careful dosage regulation. PEG, particularly in its flexible molecular weight variants, serves as a co-solvent and viscosity modifier, enhancing solubility and stability of active pharmaceutical ingredients. Pyrogen-free water, characterized by its inertness and biocompatibility, remains the gold standard for injection solvents, offering minimal risk and broad applicability across drug classes. The study underscores the importance of aligning solvent selection with the physicochemical nature of the drug, intended route of administration, and patient safety considerations. Furthermore, the potential for combining solvents to achieve optimized formulations is highlighted as a promising avenue for future pharmaceutical development. Such combinations may offer enhanced solubility, reduced toxicity, and improved delivery mechanisms, particularly for complex or poorly soluble compounds. In conclusion, understanding the nuanced roles of DMSO, PEG, and pyrogen-free water is essential for formulating safe and effective sterile injections. This research contributes to the growing body of knowledge supporting rational solvent selection and encourages further exploration into innovative solvent systems for advanced drug delivery.
References
Abdellatif, A. A. H., Ali, A. A., Alshora, D. H., & Alshahrani, S. M. (2020). Polyethylene glycol as a pharmaceutical solvent: A review of pharmacokinetics and applications in drug delivery. Journal of Drug Delivery Science and Technology, 55, 101475. https://doi.org/10.1016/j.jddst.2020.101475
Ahmad, K., Rahman, M. N., & Ali, S. (2022). DMSO as a stabilizer in peptide-based injectables. Biomed Formula Science, 40(1), 20–28.
Chen, L., Wang, Y., & Zhao, H. (2022). PEG 400 in antiviral drug development. Formula Research Letters, 19(2), 65–72.
Chen, T., Zhao, Y., Sun, J., & Wang, Y. (2020). Hypersensitivity reactions to polyethylene glycol (PEG): A growing concern. Clinical Reviews in Allergy & Immunology, 59(3), 231–245. https://doi.org/10.1007/s12016-020-08718-1
Choi, Y. J., Kim, E. S., & Ryu, H. (2021). Dimethyl sulfoxide in injectable nanoemulsions. Journal of Nanopharmaceutics, 9(3), 120–127.
Duarte, M., Gomes, F., & Silva, R. (2023). PEG 200 reduces protein aggregation in parenterals. Journal of Protein Therapeutics, 26(4), 160–168.
European Medicines Agency. (2020). Guideline on the sterilisation of the medicinal product, active substance, excipient and primary container (EMA/CHMP/CVMP/QWP/850374/2015).
Farid, M., Nordin, H., & Zulkifli, F. (2021). Controlled-release injectable using PEG 400. Controlled Drug Release Journal, 28(1), 88–96.
Food and Drug Supervisory Agency of the Republic of Indonesia. (2021). Indonesian pharmacopoeia edition VI. BPOM RI.
Hassan, A., Farooq, A., & Mehmood, R. (2019). PEG 600 for protein stability in immunotherapeutics. Stability Journal, 13(4), 98–105.
Ibrahim, F. A., Yusof, N. M., & Salleh, H. (2024). Enhancement of transdermal delivery using DMSO: A pilot study. Asian Journal of Pharmaceutics, 19(1), 33–40.
Islam, M. T., Rodríguez-Hornedo, N., & Alvarez-Núñez, F. (2022). Toxicity and dermal irritation of DMSO in parenteral preparations: A regulatory perspective. Regulatory Toxicology and Pharmacology, 127, 105083. https://doi.org/10.1016/j.yrtph.2022.105083
Jones, B. A., Miller, C. A., & Green, D. (2023). Microbiological stability of pyrogen-free water in SC biologics. Journal of Sterile Products, 48(2), 143–151.
Kumar, R., Patel, T., & Singh, P. (2020). PEG 400 for solubilization of lipophilic injectables. Therapeutic Drug Development Journal, 25(3), 78–85.
Lee, J. H., Kim, S., & Choi, D. (2020). PEG 400 as a co-solvent in injectable NSAID formulations. International Journal of Pharmaceutical Sciences, 22(4), 433–441.
Logan, D. M., White, C., & Palmer, J. (2024). DMSO for veterinary injectables: Safety assessment. Journal of Veterinary Pharmacology, 11(1), 19–27.
López-García, R., González-Paredes, A., Fernández, M., & Sánchez, I. (2023). Dimethyl sulfoxide in pharmaceutical formulations: Properties, applications, and toxicological considerations. Pharmaceuticals, 16(2), 201. https://doi.org/10.3390/ph16020201
Mishra, P., Bhutani, H., Pathak, D., & Shah, R. (2021). Formulation strategies for parenteral drug delivery: A review. International Journal of Pharmaceutical Sciences and Research, 12(5), 2445–2454.
Müller, K., Weber, T., & Schulz, H. (2020). Safety profile of PEG 400 in neurodegenerative therapies. Pharmaceutical Advances, 12(4), 307–316.
Nguyen, T. L., Hoang, T. M., & Pham, H. (2023). Pyrogen-free water in peptide drug formulations. Pharmaceutical Water Journal, 14(2), 77–84.
Nguyen, T. T., Vo, T. H., & Pham, D. H. (2022). Evidence-based selection of solvents in parenteral formulations: Toward safer injections. Journal of Pharmaceutical Innovation, 17(1), 66–75.
Oliveira, M. R., Santos, A. J., & Faria, L. (2023). Polyethylene glycol 600 in sustained-release injectables. European Journal of Pharmaceutical and Biopharmaceutical Sciences, 178, 87–94.
Park, S. H., Kwon, Y., & Kim, J. (2020). Safety of pyrogen-free water in vaccine injections: A preclinical evaluation. Pharmaceutical Science and Technology, 35(4), 354–360.
Patel, R., Desai, K., & Gohil, N. (2020). DMSO as a permeabilizer in insulin injection. Journal of Bioavailability Studies, 21(3), 50–57.
Putra, R. H., Sari, D. M., & Nurhayati, N. (2023). Validation of the endotoxin test method on water for sterile injection. Pharmaceutical Magazine, 19(1), 23–30.
Rahmawati, I., & Fitrianingsih, D. (2022). Formulation and evaluation study of injection preparations using special solvents. Journal of Indonesian Pharmaceutical Sciences, 20(2), 121–130.
Russo, G., Romano, F., & Bianchi, L. (2022). Use of DMSO as primary solvent in subcutaneous injections. Journal of Drug Delivery, 31(3), 202–210.
Smith, A., & Johnson, R. (2019). DMSO in intramuscular formulations: Opportunities and risks. Drug Delivery Reviews, 18(2), 89–97.
Suryadi, A., Kurniawan, A., & Lestari, S. D. (2021). Development of modern sterilization technology in the production of parenteral preparations. Journal of Pharmaceutical Sciences Indonesia, 8(3), 147–155.
Suzuki, N., Arai, Y., & Kato, M. (2022). Use of pyrogen-free water in COVID-19 vaccine formulation. Clinical Vaccine Formulation Journal, 30(1), 12–19.
Tan, L., Zhang, W., & Zhao, Y. (2021). PEG 200 as co-solvent in intravenous antibiotic delivery. Drug Formulary Today, 16(3), 101–108.
Wang, H., Li, Q., & Zhao, D. (2021). Evaluation of DMSO in injectable cancer formulations. Current Pharmaceutical Sciences, 17(2), 120–126.
Zhang, Y., Liu, X., & Wang, M. (2021). Dimethyl sulfoxide as a solvent in injectable cancer therapeutics. Journal of Parenteral and Enteral Drug Development, 45(3), 210–219.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Global Health: Journal of Health Sciences, Public Health and Pharmacy
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
